Literature DB >> 32285931

Nodular lichen myxoedematous: a new adverse event associated with ustekinumab.

Trinidad Montero-Vilchez1, Antonio Martinez-Lopez1,2, Carlos Cuenca-Barrales3, Aurelio Martin-Castro4, Alejandro Molina-Leyva1,2, Salvador Arias-Santiago1,2.   

Abstract

Nodular lichen myxoedematosus is a localised form of lichen myxoedematosus, a chronic idiopathic cutaneous mucinosis of known aetiology. Ustekinumab is a human interleukin-12/23 monoclonal antibody that could directly or indirectly increase mucin production. Herein, we report for the first time a case of nodular lichen myxoedematosus associated with ustekinumab.
© 2020 The Australasian College of Dermatologists.

Entities:  

Keywords:  biological therapy; drug toxicity; interleukin-23; mucins; scleromyxoedema; toxicity; ustekinumab

Mesh：

Substances：

Year:  2020        PMID： 32285931     DOI： 10.1111/ajd.13291

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN： 0004-8380            Impact factor:   2.875


  1 in total

1.  Pediatric Lichen Myxedematosus: A Diagnostic and Management Challenge.

Authors:  Kelly K Barry; Diana B Reusch; Birgitta A R Schmidt; Elena B Hawryluk
Journal:  Children (Basel)       Date:  2022-06-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.